BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tabernero J, Chiorean EG, Infante JR, Hingorani SR, Ganju V, Weekes C, Scheithauer W, Ramanathan RK, Goldstein D, Penenberg DN, Romano A, Ferrara S, Von Hoff DD. Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine vs gemcitabine alone in patients with metastatic pancreatic cancer. Oncologist. 2015;20:143-150. [PMID: 25582141 DOI: 10.1634/theoncologist.2014-0394] [Cited by in Crossref: 79] [Cited by in F6Publishing: 85] [Article Influence: 11.3] [Reference Citation Analysis]
Number Citing Articles
1 Lambert A, Schwarz L, Borbath I, Henry A, Van Laethem JL, Malka D, Ducreux M, Conroy T. An update on treatment options for pancreatic adenocarcinoma. Ther Adv Med Oncol 2019;11:1758835919875568. [PMID: 31598142 DOI: 10.1177/1758835919875568] [Cited by in Crossref: 46] [Cited by in F6Publishing: 51] [Article Influence: 15.3] [Reference Citation Analysis]
2 Braiteh F, Patel MB, Parisi M, Ni Q, Park S, Faria C. Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting. Cancer Manag Res 2017;9:141-8. [PMID: 28461766 DOI: 10.2147/CMAR.S126073] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
3 Couto GK, Segatto NV, Oliveira TL, Seixas FK, Schachtschneider KM, Collares T. The Melding of Drug Screening Platforms for Melanoma. Front Oncol 2019;9:512. [PMID: 31293965 DOI: 10.3389/fonc.2019.00512] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
4 Bruera G, Massacese S, Candria S, Galvano A, Manetta R, Giordano AV, Carducci S, Di Sibio A, Ciacco E, Russo A, Ricevuto E; Oncology Network ASL1 Abruzzo, Italy. Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study. Oncotarget 2018;9:31861-76. [PMID: 30159128 DOI: 10.18632/oncotarget.25870] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
5 Skelton WP 4th, Parekh H, Starr JS, Trevino J, Cioffi J, Hughes S, George TJ Jr. Clinical Factors as a Component of the Personalized Treatment Approach to Advanced Pancreatic Cancer: a Systematic Literature Review. J Gastrointest Cancer 2018;49:1-8. [PMID: 29110227 DOI: 10.1007/s12029-017-0021-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
6 Mohammad AA. Advanced pancreatic cancer: The standard of care and new opportunities. Oncol Rev 2018;12:370. [PMID: 30344961 DOI: 10.4081/oncol.2018.370] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
7 Metelmann H, Nedrelow DS, Seebauer C, Schuster M, von Woedtke T, Weltmann K, Kindler S, Metelmann PH, Finkelstein SE, Von Hoff DD, Podmelle F. Head and neck cancer treatment and physical plasma. Clinical Plasma Medicine 2015;3:17-23. [DOI: 10.1016/j.cpme.2015.02.001] [Cited by in Crossref: 119] [Cited by in F6Publishing: 43] [Article Influence: 17.0] [Reference Citation Analysis]
8 Segelov E, Lordick F, Goldstein D, Chantrill LA, Croagh D, Lawrence B, Arnold D, Chau I, Obermannova R, Price TJ. Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Rev Anticancer Ther 2017;17:951-64. [PMID: 28817982 DOI: 10.1080/14737140.2017.1369882] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
9 Vivaldi C, Fornaro L, Cappelli C, Pecora I, Catanese S, Salani F, Cacciato Insilla A, Kauffmann E, Donati F, Pasquini G, Massa V, Napoli N, Lencioni M, Boraschi P, Campani D, Boggi U, Caramella D, Falcone A, Vasile E. Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study. Cancers (Basel) 2019;11:E939. [PMID: 31277449 DOI: 10.3390/cancers11070939] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Goldstein D, Von Hoff DD, Chiorean EG, Reni M, Tabernero J, Ramanathan RK, Botteman M, Aly A, Margunato-Debay S, Lu B, Louis CU, McGovern D, Lee CK. Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic Cancer. Pancreas 2020;49:744-50. [PMID: 32541630 DOI: 10.1097/MPA.0000000000001563] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Iede K, Yamada T, Kato R, Ueda M, Tsuda Y, Nakashima S, Ohta K, Matsuyama J, Ikenaga M, Tominaga S. Efficacy of S-1 in second-line chemotherapy after nab-paclitaxel plus gemcitabine for patients with advanced pancreatic cancer. Cancer Rep (Hoboken) 2020;3:e1215. [PMID: 32672000 DOI: 10.1002/cnr2.1215] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Guo Y, Ding Y, Li D, Li J, Peng R, Wen X, Zhang X, Zhang X. Efficacy and safety of nab-paclitaxel combined with carboplatin in Chinese patients with melanoma. Med Oncol 2015;32. [DOI: 10.1007/s12032-015-0679-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
13 Kokkali S, Tripodaki ES, Drizou M, Stefanou D, Magou E, Zylis D, Kapiris M, Nasi D, Georganta C, Ardavanis A. Biweekly Gemcitabine/Nab-Paclitaxel as First-line Treatment for Advanced Pancreatic Cancer. In Vivo 2018;32:653-7. [PMID: 29695574 DOI: 10.21873/invivo.11289] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
14 Goldstein D, Von Hoff DD, Moore M, Greeno E, Tortora G, Ramanathan RK, Macarulla T, Liu H, Pilot R, Ferrara S. Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT). Eur J Cancer. 2016;52:85-91. [PMID: 26655559 DOI: 10.1016/j.ejca.2015.10.017] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
15 Tehfe M, Dowden S, Kennecke H, El-Maraghi R, Lesperance B, Couture F, Letourneau R, Liu H, Romano A. nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial. Adv Ther 2016;33:747-59. [PMID: 27085323 DOI: 10.1007/s12325-016-0327-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
16 Wu L, Zhu L, Xu K, Zhou S, Zhou Y, Zhang T, Hang J, Zee BC. Clinical significance of site-specific metastases in pancreatic cancer: a study based on both clinical trial and real-world data. J Cancer 2021;12:1715-21. [PMID: 33613759 DOI: 10.7150/jca.50317] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Graversen M, Detlefsen S, Bjerregaard JK, Fristrup CW, Pfeiffer P, Mortensen MB. Prospective, single-center implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis. Ther Adv Med Oncol 2018;10:1758835918777036. [PMID: 29899763 DOI: 10.1177/1758835918777036] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 6.5] [Reference Citation Analysis]
18 Chiorean EG, Von Hoff DD, Reni M, Arena FP, Infante JR, Bathini VG, Wood TE, Mainwaring PN, Muldoon RT, Clingan PR, Kunzmann V, Ramanathan RK, Tabernero J, Goldstein D, McGovern D, Lu B, Ko A. CA19-9 decrease at 8 wk as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine vs gemcitabine alone in patients with metastatic pancreatic cancer. Ann Oncol. 2016;27:654-660. [PMID: 26802160 DOI: 10.1093/annonc/mdw006] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 8.0] [Reference Citation Analysis]
19 Ebelt ND, Zuniga E, Passi KB, Sobocinski LJ, Manuel ER. Hyaluronidase-Expressing Salmonella Effectively Targets Tumor-Associated Hyaluronic Acid in Pancreatic Ductal Adenocarcinoma. Mol Cancer Ther 2020;19:706-16. [PMID: 31694889 DOI: 10.1158/1535-7163.MCT-19-0556] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
20 Manrai M, Tilak TVSVGK, Dawra S, Srivastava S, Singh A. Current and emerging therapeutic strategies in pancreatic cancer: Challenges and opportunities. World J Gastroenterol 2021; 27(39): 6572-6589 [PMID: 34754153 DOI: 10.3748/wjg.v27.i39.6572] [Reference Citation Analysis]
21 Hegewisch-Becker S, Aldaoud A, Wolf T, Krammer-Steiner B, Linde H, Scheiner-Sparna R, Hamm D, Jänicke M, Marschner N; TPK-Group (Tumour Registry Pancreatic Cancer). Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma. Int J Cancer 2019;144:981-90. [PMID: 30006989 DOI: 10.1002/ijc.31751] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
22 White MN, Dotan E, Catalano PJ, Cardin DB, Berlin JD. Advanced pancreatic cancer clinical trials: The continued underrepresentation of older patients. J Geriatr Oncol 2019;10:540-6. [PMID: 30573201 DOI: 10.1016/j.jgo.2018.11.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
23 Williet N, Saint A, Pointet AL, Tougeron D, Pernot S, Pozet A, Bechade D, Trouilloud I, Lourenco N, Hautefeuille V, Locher C, Desrame J, Artru P, Thirot Bidault A, Le Roy B, Pezet D, Phelip JM, Taieb J. Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study. Therap Adv Gastroenterol 2019;12:1756284819878660. [PMID: 31598136 DOI: 10.1177/1756284819878660] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
24 Neuzillet C, Gaujoux S, Williet N, Bachet JB, Bauguion L, Colson Durand L, Conroy T, Dahan L, Gilabert M, Huguet F, Marthey L, Meilleroux J, de Mestier L, Napoléon B, Portales F, Sa Cunha A, Schwarz L, Taieb J, Chibaudel B, Bouché O, Hammel P; Thésaurus National de Cancérologie Digestive (TNCD)., Société Nationale Française de Gastroentérologie (SNFGE)., Fédération Francophone de Cancérologie Digestive (FFCD)., Groupe Coopérateur multidisciplinaire en Oncologie (GERCOR)., Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER)., Société Française de Chirurgie Digestive (SFCD)., Société Française d’Endoscopie Digestive (SFED)., Société Française de Radiothérapie Oncologique (SFRO)., Association de Chirurgie Hépato-Bilio-Pancréatique et Transplantation (ACHBT)., Association Française de Chirurgie (AFC). Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). Dig Liver Dis 2018;50:1257-71. [PMID: 30219670 DOI: 10.1016/j.dld.2018.08.008] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 13.3] [Reference Citation Analysis]
25 Martín AM, Hidalgo M, Alvarez R, Arrazubi V, Martínez-Galán J, Salgado M, Macarulla T, Carrato A. From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer. J Cancer 2018;9:1978-88. [PMID: 29896283 DOI: 10.7150/jca.23716] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
26 Giordano G, Pancione M, Olivieri N, Parcesepe P, Velocci M, Di Raimo T, Coppola L, Toffoli G, D’Andrea MR. Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions. World J Gastroenterol 2017; 23(32): 5875-5886 [PMID: 28932079 DOI: 10.3748/wjg.v23.i32.5875] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 35] [Article Influence: 8.2] [Reference Citation Analysis]
27 Macarulla T, Pazo-cid R, Guillén-ponce C, López R, Vera R, Reboredo M, Muñoz Martin A, Rivera F, Díaz Beveridge R, La Casta A, Martín Valadés J, Martínez-galán J, Ales I, Sastre J, Perea S, Hidalgo M. Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2. JCO 2019;37:230-8. [DOI: 10.1200/jco.18.00089] [Cited by in Crossref: 35] [Cited by in F6Publishing: 15] [Article Influence: 11.7] [Reference Citation Analysis]
28 Tabernero J, Kunzmann V, Scheithauer W, Reni M, Shiansong Li J, Ferrara S, Djazouli K. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial. Onco Targets Ther 2017;10:591-6. [PMID: 28203092 DOI: 10.2147/OTT.S124097] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
29 Macarulla T, Carrato A, Díaz R, García A, Laquente B, Sastre J, Álvarez R, Muñoz A, Hidalgo M. Management and supportive treatment of frail patients with metastatic pancreatic cancer. J Geriatr Oncol 2019;10:398-404. [PMID: 30005980 DOI: 10.1016/j.jgo.2018.06.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
30 Kunzmann V, Ramanathan RK, Goldstein D, Liu H, Ferrara S, Lu B, Renschler MF, Von Hoff DD. Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 Study. Pancreas. 2017;46:203-208. [PMID: 27841795 DOI: 10.1097/mpa.0000000000000742] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
31 Combs SE. Individualized radiotherapy (iRT) concepts for locally advanced pancreatic cancer (LAPC): indications and prognostic factors. Langenbecks Arch Surg 2015;400:749-56. [DOI: 10.1007/s00423-015-1309-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
32 Chakupurakal G, Feiten S, Burkhard O, Reiser M, Ehscheidt P, Weide R. Successful Evidence-Based Treatment of Patients with Advanced Pancreatic Cancer in Community-Based Oncology Group Practices. Oncol Res Treat 2017;40:784-8. [PMID: 29183029 DOI: 10.1159/000480016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
33 Ventriglia J, Petrillo A, Huerta Alváro M, Laterza MM, Savastano B, Gambardella V, Tirino G, Pompella L, Diana A, Iovino F, Troiani T, Martinelli E, Morgillo F, Orditura M, Cervantes A, Ciardiello F, De Vita F. Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis. Gastroenterol Res Pract 2018;2018:2373868. [PMID: 29983708 DOI: 10.1155/2018/2373868] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
34 Oweira H, Petrausch U, Helbling D, Schmidt J, Mannhart M, Mehrabi A, Schöb O, Giryes A, Decker M, Abdel-Rahman O. Prognostic value of site-specific metastases in pancreatic adenocarcinoma: A Surveillance Epidemiology and End Results database analysis. World J Gastroenterol 2017; 23(10): 1872-1880 [PMID: 28348494 DOI: 10.3748/wjg.v23.i10.1872] [Cited by in CrossRef: 67] [Cited by in F6Publishing: 62] [Article Influence: 13.4] [Reference Citation Analysis]
35 Scheithauer W, Ramanathan RK, Moore M, Macarulla T, Goldstein D, Hammel P, Kunzmann V, Liu H, McGovern D, Romano A. Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial. J Gastrointest Oncol. 2016;7:469-478. [PMID: 27284481 DOI: 10.21037/jgo.2016.01.03] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
36 Kang J, Hwang I, Yoo C, Kim KP, Jeong JH, Chang HM, Lee SS, Park DH, Song TJ, Seo DW, Lee SK, Kim MH, Hong SM, Shin SH, Hwang DW, Song KB, Lee JH, Kim SC, Ryoo BY. Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis. Invest New Drugs. 2018;36:732-741. [PMID: 29616439 DOI: 10.1007/s10637-018-0598-5] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 14.5] [Reference Citation Analysis]
37 Blomstrand H, Green H, Fredrikson M, Gränsmark E, Björnsson B, Elander NO. Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel. BMC Cancer 2020;20:950. [PMID: 33008332 DOI: 10.1186/s12885-020-07426-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Graversen M, Detlefsen S, Bjerregaard JK, Pfeiffer P, Mortensen MB. Peritoneal metastasis from pancreatic cancer treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC). Clin Exp Metastasis. 2017;34:309-314. [PMID: 28516306 DOI: 10.1007/s10585-017-9849-7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 7.4] [Reference Citation Analysis]
39 Rotolo S, Ferracci F, Santullo F, Lodoli C, Inzani F, Abatini C, Pacelli F, Di Giorgio A. Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A case report of a multimodal treatment for peritoneal metastases of pancreatic origin. Int J Surg Case Rep 2020;77S:S75-8. [PMID: 33191190 DOI: 10.1016/j.ijscr.2020.10.054] [Reference Citation Analysis]
40 Lambert A, Gavoille C, Conroy T. Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions. Therap Adv Gastroenterol 2017;10:631-45. [PMID: 28835777 DOI: 10.1177/1756283X17713879] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
41 De Luca R, Blasi L, Alù M, Gristina V, Cicero G. Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer. Drug Des Devel Ther 2018;12:1769-75. [PMID: 29950811 DOI: 10.2147/DDDT.S165851] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
42 Ishimoto U, Kinoshita A, Hirose Y, Shibata K, Ishii A, Shoji R, Yokota T, Iwaku A, Mizuno Y, Koike K, Saruta M. The efficacy and safety of nab paclitaxel plus gemcitabine in elderly patients over 75 years with unresectable pancreatic cancer compared with younger patients. Cancer Chemother Pharmacol 2019;84:647-54. [DOI: 10.1007/s00280-019-03895-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
43 Colloca G. Performance status as prognostic factor in phase III trials of first-line chemotherapy of unresectable or metastatic pancreatic cancer: A trial-level meta-analysis. Asia Pac J Clin Oncol 2021. [PMID: 34161667 DOI: 10.1111/ajco.13598] [Reference Citation Analysis]
44 Meijer LL, Garajová I, Caparello C, Le Large TYS, Frampton AE, Vasile E, Funel N, Kazemier G, Giovannetti E. Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma. Ann Surg 2020;271:1137-47. [PMID: 30394883 DOI: 10.1097/SLA.0000000000003084] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
45 Hwang I, Kang J, Ip HNN, Jeong JH, Kim KP, Chang HM, Yoo C, Ryoo BY. Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores. Invest New Drugs. 2019;37:584-590. [PMID: 30324344 DOI: 10.1007/s10637-018-0681-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
46 Avula LR, Hagerty B, Alewine C. Molecular mediators of peritoneal metastasis in pancreatic cancer. Cancer Metastasis Rev 2020;39:1223-43. [PMID: 32780245 DOI: 10.1007/s10555-020-09924-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
47 Ouyang H, Ma W, Liu F, Yue Z, Fang M, Quan M, Pan Z. Factors influencing survival of patients with pancreatic adenocarcinoma and synchronous liver metastases receiving palliative care. Pancreatology 2017;17:773-81. [PMID: 28734721 DOI: 10.1016/j.pan.2017.07.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
48 McLellan P, Henriques J, Ksontini F, Doat S, Hammel P, Desrame J, Trouilloud I, Louvet C, Pietrasz D, Vernerey D, Bachet JB. Prognostic value of the early change in neutrophil-to-lymphocyte ratio in metastatic pancreatic adenocarcinoma. Clin Res Hepatol Gastroenterol 2021;45:101541. [PMID: 33055007 DOI: 10.1016/j.clinre.2020.08.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
49 Chun JW, Lee SH, Kim JS, Park N, Huh G, Cho IR, Paik WH, Ryu JK, Kim YT. Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach. BMC Cancer 2021;21:537. [PMID: 33975561 DOI: 10.1186/s12885-021-08277-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
50 van der Geest LGM, Haj Mohammad N, Besselink MGH, Lemmens VEPP, Portielje JEA, van Laarhoven HWM, Wilmink JHW; Dutch Pancreatic Cancer Group. Nationwide trends in chemotherapy use and survival of elderly patients with metastatic pancreatic cancer. Cancer Med 2017;6:2840-9. [PMID: 29035014 DOI: 10.1002/cam4.1240] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
51 Thillai K, Sarker D, Ross P. Progress in pancreatic cancer therapeutics: The potential to exploit molecular targets. World J Pharmacol 2015; 4(2): 180-192 [DOI: 10.5497/wjp.v4.i2.180] [Reference Citation Analysis]
52 Blaszak M, El-Masri M, Hirmiz K, Mathews J, Omar A, Elfiki T, Gupta R, Hamm C, Kanjeekal S, Kay A, Kulkarni S, Ghafoor A. Survival of patients with pancreatic cancer treated with varied modalities: A single-centre study. Mol Clin Oncol 2017;6:583-8. [PMID: 28413673 DOI: 10.3892/mco.2017.1179] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
53 Yang WW, Yang L, Lu HZ, Sun YK. Long-term survival of a patient with pancreatic cancer and lung metastasis: A case report and review of literature. World J Clin Cases 2021; 9(30): 9134-9143 [PMID: 34786397 DOI: 10.12998/wjcc.v9.i30.9134] [Reference Citation Analysis]
54 Ter Veer E, van Rijssen LB, Besselink MG, Mali RMA, Berlin JD, Boeck S, Bonnetain F, Chau I, Conroy T, Van Cutsem E, Deplanque G, Friess H, Glimelius B, Goldstein D, Herrmann R, Labianca R, Van Laethem JL, Macarulla T, van der Meer JHM, Neoptolemos JP, Okusaka T, O'Reilly EM, Pelzer U, Philip PA, van der Poel MJ, Reni M, Scheithauer W, Siveke JT, Verslype C, Busch OR, Wilmink JW, van Oijen MGH, van Laarhoven HWM. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Lancet Oncol 2018;19:e151-60. [PMID: 29508762 DOI: 10.1016/S1470-2045(18)30098-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
55 Werthmann PG, Inter P, Welsch T, Sturm AK, Grützmann R, Debus M, Sterner MG, Kienle GS. Long-term tumor-free survival in a metastatic pancreatic carcinoma patient with FOLFIRINOX/Mitomycin, high-dose, fever inducing Viscum album extracts and subsequent R0 resection: A case report.Medicine (Baltimore). 2018;97:e13243. [PMID: 30544385 DOI: 10.1097/MD.0000000000013243] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Edwards P, Kang BW, Chau I. Targeting the Stroma in the Management of Pancreatic Cancer. Front Oncol 2021;11:691185. [PMID: 34336679 DOI: 10.3389/fonc.2021.691185] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
57 Verdaguer H, Saurí T, Macarulla T. Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment. J Gastrointest Oncol 2017;8:405-17. [PMID: 28736628 DOI: 10.21037/jgo.2016.11.15] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
58 Sawada M, Kasuga A, Mie T, Furukawa T, Taniguchi T, Fukuda K, Yamada Y, Takeda T, Kanata R, Matsuyama M, Sasaki T, Ozaka M, Sasahira N. Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer. BMC Cancer 2020;20:449. [PMID: 32434547 DOI: 10.1186/s12885-020-06945-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
59 Grapsa D, Saif MW, Syrigos K. Targeted therapies for pancreatic adenocarcinoma: Where do we stand, how far can we go? World J Gastrointest Oncol 2015; 7(10): 172-177 [PMID: 26483872 DOI: 10.4251/wjgo.v7.i10.172] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
60 Morita S, Arai Y, Sugawara S, Sone M, Sakamoto Y, Okusaka T, Yoshinaga S, Saito Y, Terai S. Antireflux Metal Stent for Initial Treatment of Malignant Distal Biliary Obstruction. Gastroenterol Res Pract 2018;2018:3805173. [PMID: 29643916 DOI: 10.1155/2018/3805173] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
61 Iede K, Yamada T, Kato R, Ueda M, Tsuda Y, Nakashima S, Ohta K, Matsuyama J, Ikenaga M, Tominaga S. Predictive implications of decreased CA19-9 at 8 weeks during nab-paclitaxel plus gemcitabine for the induction of second-line chemotherapy for patients with advanced pancreatic cancer. Cancer Rep (Hoboken) 2020;3:e1289. [PMID: 32969199 DOI: 10.1002/cnr2.1289] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
62 Bonnet E, Mastier C, Lardy-Cléaud A, Rochefort P, Sarabi M, Guibert P, Cattey-Javouhey A, Desseigne F, de La Fouchardière C. FOLFIRINOX in patients with peritoneal carcinomatosis from pancreatic adenocarcinoma: a retrospective study. Curr Oncol 2019;26:e466-72. [PMID: 31548814 DOI: 10.3747/co.26.4903] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
63 Werthmann PG, Kempenich R, Lang-Avérous G, Kienle GS. Long-term survival of a patient with advanced pancreatic cancer under adjunct treatment with Viscum album extracts: A case report. World J Gastroenterol 2019; 25(12): 1524-1530 [PMID: 30948915 DOI: 10.3748/wjg.v25.i12.1524] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
64 Vivaldi C, Caparello C, Musettini G, Pasquini G, Catanese S, Fornaro L, Lencioni M, Falcone A, Vasile E. First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors. Int J Cancer. 2016;139:938-945. [PMID: 27038273 DOI: 10.1002/ijc.30125] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
65 Nielsen M, Graversen M, Ellebæk SB, Kristensen TK, Fristrup C, Pfeiffer P, Mortensen MB, Detlefsen S. Next-generation sequencing and histological response assessment in peritoneal metastasis from pancreatic cancer treated with PIPAC. J Clin Pathol 2021;74:19-24. [PMID: 32385139 DOI: 10.1136/jclinpath-2020-206607] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
66 Gallego J, López C, Pazo-cid R, López-ríos F, Carrato A. Biomarkers in pancreatic ductal adenocarcinoma. Clin Transl Oncol 2017;19:1430-7. [DOI: 10.1007/s12094-017-1691-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
67 Khosrawipour T, Khosrawipour V, Giger-Pabst U. Pressurized Intra Peritoneal Aerosol Chemotherapy in patients suffering from peritoneal carcinomatosis of pancreatic adenocarcinoma. PLoS One. 2017;12:e0186709. [PMID: 29049340 DOI: 10.1371/journal.pone.0186709] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
68 Khomiak A, Brunner M, Kordes M, Lindblad S, Miksch RC, Öhlund D, Regel I. Recent Discoveries of Diagnostic, Prognostic and Predictive Biomarkers for Pancreatic Cancer. Cancers (Basel) 2020;12:E3234. [PMID: 33147766 DOI: 10.3390/cancers12113234] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
69 Javed MA, Beyer G, Le N, Vinci A, Wong H, Palmer D, Morgan RD, Lamarca A, Hubner RA, Valle JW, Alam S, Chowdhury S, Ma YT, Archibugi L, Capurso G, Maisonneuve P, Neesse A, Sund M, Schober M, Krug S. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe. Pancreatology. 2019;19:97-104. [PMID: 30529068 DOI: 10.1016/j.pan.2018.10.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
70 Horvath P, Beckert S, Struller F, Königsrainer A, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastases of pancreas and biliary tract cancer. Clin Exp Metastasis 2018;35:635-40. [PMID: 30062506 DOI: 10.1007/s10585-018-9925-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
71 Lund-Andersen C, Torgunrud A, Fleten KG, Flatmark K. Omics analyses in peritoneal metastasis-utility in the management of peritoneal metastases from colorectal cancer and pseudomyxoma peritonei: a narrative review. J Gastrointest Oncol 2021;12:S191-203. [PMID: 33968437 DOI: 10.21037/jgo-20-136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Prager GW, Oehler L, Gerger A, Mlineritsch B, Andel J, Petzer A, Wilthoner K, Sliwa T, Pichler P, Winder T, Heibl S, Gruenberger B, Laengle F, Hubmann E, Korger M, Pecherstorfer M, Djanani A, Neumann HJ, Philipp-Abbrederis K, Wöll E, Trondl R, Arnold-Schrauf C, Eisterer W. Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional study. Eur J Cancer 2021;143:101-12. [PMID: 33296830 DOI: 10.1016/j.ejca.2020.11.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
73 Iede K, Yamada T, Kato R, Ueda M, Tsuda Y, Nakashima S, Ohta K, Matsuyama J, Ikenaga M, Tominaga S. Multiple Liver Metastases Rather Than the Presence of Liver Metastasis Is a Significantly Poor Prognostic Factor for Patients With Advanced Pancreatic Cancer. Pancreas 2020;49:e63-5. [PMID: 32675786 DOI: 10.1097/MPA.0000000000001596] [Reference Citation Analysis]
74 Baron MK, Wang X, Nevala-Plagemann C, Moser JC, Haaland B, Garrido-Laguna I. Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma. Pancreas 2021;50:796-802. [PMID: 34347727 DOI: 10.1097/MPA.0000000000001844] [Reference Citation Analysis]
75 Fornaro L, Leone F, Vienot A, Casadei-Gardini A, Vivaldi C, Lièvre A, Lombardi P, De Luca E, Vernerey D, Sperti E, Musettini G, Satolli MA, Edeline J, Spadi R, Neuzillet C, Falcone A, Pasquini G, Clerico M, Passardi A, Buscaglia P, Meurisse A, Aglietta M, Brac C, Vasile E, Montagnani F. Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan. Clin Colorectal Cancer 2019;18:e394-401. [PMID: 31564556 DOI: 10.1016/j.clcc.2019.08.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
76 De Vita F, Ventriglia J, Febbraro A, Laterza MM, Fabozzi A, Savastano B, Petrillo A, Diana A, Giordano G, Troiani T, Conzo G, Galizia G, Ciardiello F, Orditura M. NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice. BMC Cancer 2016;16:709. [PMID: 27590845 DOI: 10.1186/s12885-016-2671-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
77 You MS, Ryu JK, Choi YH, Choi JH, Huh G, Paik WH, Lee SH, Kim YT. Efficacy of Nab-Paclitaxel Plus Gemcitabine and Prognostic Value of Peripheral Neuropathy in Patients with Metastatic Pancreatic Cancer. Gut Liver 2018;12:728-35. [PMID: 30400731 DOI: 10.5009/gnl18220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
78 Mohile SG, Magnuson A, Pandya C, Velarde C, Duberstein P, Hurria A, Loh KP, Wells M, Plumb S, Gilmore N, Flannery M, Wittink M, Epstein R, Heckler CE, Janelsins M, Mustian K, Hopkins JO, Liu J, Peri S, Dale W. Community Oncologists' Decision-Making for Treatment of Older Patients With Cancer. J Natl Compr Canc Netw 2018;16:301-9. [PMID: 29523669 DOI: 10.6004/jnccn.2017.7047] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 9.7] [Reference Citation Analysis]
79 Shin K, Jung EK, Park SJ, Jeong S, Kim IH, Lee MA. Neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 as prognostic markers for advanced pancreatic cancer patients receiving first-line chemotherapy. World J Gastrointest Oncol 2021; 13(8): 915-928 [PMID: 34457195 DOI: 10.4251/wjgo.v13.i8.915] [Reference Citation Analysis]
80 Kubo K, Wadasaki K, Komichi D, Sasaki T, Yamada H, Matsugu Y, Itamoto T, Doi M, Shinozaki K. A single institution experience of the treatment of pancreatic ductal carcinoma: The demand and the role of radiation therapy. PLoS One 2019;14:e0227305. [PMID: 31887205 DOI: 10.1371/journal.pone.0227305] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
81 Deng GC, Sun DC, Zhou Q, Lv Y, Yan H, Han QL, Dai GH. Identification of DNA methylation-driven genes and construction of a nomogram to predict overall survival in pancreatic cancer. BMC Genomics 2021;22:791. [PMID: 34732125 DOI: 10.1186/s12864-021-08097-w] [Reference Citation Analysis]
82 Cheng SH, Cheng YJ, Jin ZY, Xue HD. Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy. Eur J Radiol. 2019;113:188-197. [PMID: 30927946 DOI: 10.1016/j.ejrad.2019.02.009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
83 Kadokura M, Ishida Y, Tatsumi A, Takahashi E, Shindo H, Amemiya F, Takano S, Fukasawa M, Sato T, Enomoto N. Performance status and neutrophil-lymphocyte ratio are important prognostic factors in elderly patients with unresectable pancreatic cancer. J Gastrointest Oncol 2016;7:982-8. [PMID: 28078122 DOI: 10.21037/jgo.2016.06.06] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
84 Parente P, Parcesepe P, Covelli C, Olivieri N, Remo A, Pancione M, Latiano TP, Graziano P, Maiello E, Giordano G. Crosstalk between the Tumor Microenvironment and Immune System in Pancreatic Ductal Adenocarcinoma: Potential Targets for New Therapeutic Approaches. Gastroenterol Res Pract. 2018;2018:7530619. [PMID: 30662458 DOI: 10.1155/2018/7530619] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
85 Di Giorgio A, Sgarbura O, Rotolo S, Schena CA, Bagalà C, Inzani F, Russo A, Chiantera V, Pacelli F. Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin or oxaliplatin for peritoneal metastasis from pancreatic adenocarcinoma and cholangiocarcinoma. Ther Adv Med Oncol 2020;12:1758835920940887. [PMID: 32782488 DOI: 10.1177/1758835920940887] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
86 Riedl JM, Posch F, Prager G, Eisterer W, Oehler L, Sliwa T, Wilthoner K, Petzer A, Pichler P, Hubmann E, Winder T, Burgstaller S, Korger M, Andel J, Greil R, Neumann HJ, Pecherstorfer M, Philipp-Abbrederis K, Djanani A, Gruenberger B, Laengle F, Wöll E, Gerger A. The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc analysis of an Austrian multicenter, noninterventional study. Ther Adv Med Oncol 2020;12:1758835919900872. [PMID: 32313566 DOI: 10.1177/1758835919900872] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
87 Gargiulo P, Dietrich D, Herrmann R, Bodoky G, Ruhstaller T, Scheithauer W, Glimelius B, Berardi S, Pignata S, Brauchli P. Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores. Ther Adv Med Oncol 2019;11:1758835918818351. [PMID: 30636977 DOI: 10.1177/1758835918818351] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]